<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03859973</url>
  </required_header>
  <id_info>
    <org_study_id>1346-0038</org_study_id>
    <secondary_id>2018-002740-82</secondary_id>
    <nct_id>NCT03859973</nct_id>
  </id_info>
  <brief_title>This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With Schizophrenia</brief_title>
  <official_title>A Phase II Randomized, Double-blinded, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of BI 425809 Once Daily With Adjunctive Computerized Cognitive Training Over 12 Week Treatment Period in Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study in adults with schizophrenia. The study tests whether a medicine called BI&#xD;
      425809 together with brain training improves mental abilities.&#xD;
&#xD;
      Participants take study medication once a day for 12 weeks. At the start of the study, the&#xD;
      participants are put into 2 groups. It is decided by chance who gets into which group. One&#xD;
      group gets BI 425809 tablets every day. The other group gets placebo tablets every day.&#xD;
      Placebo tablets look like the BI 425809 tablets, but contain no medicine. During the study,&#xD;
      all participants do brain training using a computer.&#xD;
&#xD;
      The doctors regularly test mental abilities of the participants. The results of the mental&#xD;
      ability tests are compared between the groups. The doctors also check the general health of&#xD;
      the patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2019</start_date>
  <completion_date type="Anticipated">July 8, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 10, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in neurocognitive function as measured by the neurocognitive composite score of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB)</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cognitive function as measured by the overall MCCB composite score (including social cognition)</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the effect of cognitive deficit on day-to-day functioning as measured by SCoRS total score</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Schizophrenia Cognition Rating Scale (SCoRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Positive and Negative Syndrome Scale (PANSS) total score</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Positive and Negative Syndrome Scale (PANSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with (S)AEs</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>BI 425809</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active drug treatment arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo drug arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 425809</intervention_name>
    <description>Tablet</description>
    <arm_group_label>BI 425809</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed and dated written informed consent in accordance with ICH Harmonized Tripartite&#xD;
             Guideline for Good Clinical Practice (ICH-GCP) and local legislation prior to&#xD;
             admission to the trial.&#xD;
&#xD;
          -  Male or female patients who are 18-50 years (inclusive) of age at time of consent.&#xD;
&#xD;
          -  Established schizophrenia (as per DSM-5) with the following clinical features:&#xD;
&#xD;
               -  Outpatient, with no hospitalization for worsening of schizophrenia within 3&#xD;
                  months prior to randomization&#xD;
&#xD;
               -  Psychiatrically stable without symptom exacerbation within 3 months prior to&#xD;
                  randomization&#xD;
&#xD;
               -  PANSS score ≤ 5 on positive items P1, P3-P7 and ≤ 4 on positive item P2 at Visit&#xD;
                  1, and confirmed at Visit 2&#xD;
&#xD;
          -  Patients must be on stable antipsychotic treatment; also, current antipsychotic&#xD;
             medications and concomitant anticholinergics, antiepileptics, lithium and allowed&#xD;
             antidepressants must meet the criteria below:&#xD;
&#xD;
               -  Patients must take 1 and may take up to 2 antipsychotics (typical and/or&#xD;
                  atypical), except for clozapine&#xD;
&#xD;
               -  Patients must be stable on current antipsychotics, anticholinergics,&#xD;
                  antiepileptics, lithium and allowed antidepressants for at least 3 months prior&#xD;
                  to randomization and be on current dose for at least 30 days prior to&#xD;
                  randomization o Patients on Long-Acting Injectable (LAI) antipsychotics should be&#xD;
                  on the same medication and dose for at least 3 months prior to randomization&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP)2 must be ready and able to use highly&#xD;
             effective methods of birth control per Non-Clinical Safety Studies for the Conduct of&#xD;
             Human Clinical Trials and Marketing Authorization for Pharmaceuticals (ICH M3 (R2))&#xD;
             that result in a low failure rate of less than 1% per year when used consistently and&#xD;
             correctly. A list of contraception methods meeting these criteria is provided in&#xD;
             Section 4.2.2.3. Such methods should be used throughout the trial, and for a period of&#xD;
             at least 35 days after last trial drug intake, and the patient must agree to periodic&#xD;
             pregnancy testing during participation in the trial.&#xD;
&#xD;
          -  Patients must demonstrate their ability to properly use the CCT device and program, as&#xD;
             well as be compliant with CCT run-in (defined as completing at least 2 hours per week&#xD;
             for two weeks, totalling 4 hours CCT, during the screening period)3.&#xD;
&#xD;
          -  Patients must be able to comply with all protocol procedures, in the investigator's&#xD;
             opinion.&#xD;
&#xD;
          -  Patients must have a study partner who will preferably be consistent throughout the&#xD;
             study. It is recommended that the study partner should interact (in-person or&#xD;
             telephone) with the subject at least 2 times a week.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have a categorical diagnosis of another current major psychiatric&#xD;
             disorder on the Mini-International Neuropsychiatric Interview (M.I.N.I.).&#xD;
&#xD;
          -  Diseases of the central nervous system (CNS) that may impact the assessment of the&#xD;
             cognitive tests as per investigator's opinion. A movement disorder due to&#xD;
             antipsychotic treatment not currently controlled with anti- EPS treatment or another&#xD;
             movement disorder (e.g. Parkinson´s disease).&#xD;
&#xD;
          -  Patients with a history of participating in any formal cognitive remediation program&#xD;
             for 10 or more training sessions.&#xD;
&#xD;
          -  Patients who were treated with any of the following medications within the last 6&#xD;
             months prior to randomization:&#xD;
&#xD;
               -  Bitopertin, BI 409306, encenicline or other investigational drug testing effects&#xD;
                  on cognition in schizophrenia&#xD;
&#xD;
               -  Clozapine (atypical antipsychotic medication)&#xD;
&#xD;
               -  Sarcosine, cycloserine, serine and glycine&#xD;
&#xD;
               -  Stimulants (e.g. methylphenidate, dextroamphetamine, modafinil)&#xD;
&#xD;
               -  Tricyclic antidepressants&#xD;
&#xD;
          -  Patients receiving any other investigational drug (other than a potential cognitive&#xD;
             enhancing drug) within 30 days or 6 half-lives (whichever is longer) prior to&#xD;
             randomization. For investigational LAI antipsychotics, the last injection must be at&#xD;
             least 3 months or two administration cycles (i.e. 6 months if administration is every&#xD;
             3 months) prior to randomization, whichever is longer.&#xD;
&#xD;
          -  Patients who have participated in a clinical trial with repeated assessments (i.e. a&#xD;
             single assessment is not exclusionary) with the MATRICS Consensus Cognitive Battery&#xD;
             (MCCB) within the last 6 months prior to randomization.&#xD;
&#xD;
          -  Patients who required a change in ongoing benzodiazepine or sleep medication dose or&#xD;
             regimen within the last 30 days prior to randomization.&#xD;
&#xD;
          -  Patients with known active infection with SARS-CoV-2 within the last 30 days prior to&#xD;
             randomization.&#xD;
&#xD;
          -  Other exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Atria Clinical Research</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Woodland Research Northwest</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network, LLC (CNS)</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Walling</last_name>
      <phone>+001(714)799-7799</phone>
      <email>davidwalling@cnstrial.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Synergy San Diego</name>
      <address>
        <city>Lemon Grove</city>
        <state>California</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed Bari</last_name>
      <phone>+001(619)303-6130</phone>
      <email>bari@synergysandiego.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Catalina Research Institute, LLC</name>
      <address>
        <city>Montclair</city>
        <state>California</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Pacific Research Partners, LLC</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>NRC Research Institute</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Chueh</last_name>
      <phone>+001(714)335-3015</phone>
      <email>dchueh@nrcresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asclepes Research Centers</name>
      <address>
        <city>Panorama City</city>
        <state>California</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anil Sharma</last_name>
      <phone>+001(310)208-7144</phone>
      <email>Asharma@asclepes.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CNRI - Los Angeles</name>
      <address>
        <city>Pico Rivera</city>
        <state>California</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymond Manning</last_name>
      <phone>+001(562)928-8601</phone>
      <email>raymond.manning@cnrilallc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CNRI-San Diego, LLC</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Benbow</last_name>
      <phone>+001(619)481-5252</phone>
      <email>Christopher.benbow@cnrisandiego.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network, LLC (CNS)</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Marraffino</last_name>
      <phone>+001(407)644-1165</phone>
      <email>amarraffino@meridienresearch.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilio Mantero-Atienza</last_name>
      <phone>+001(305)392-0279</phone>
      <email>emantero@pcrinstitute.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Apalachee Center</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Jerome Golden Center for Behavioral Health</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Synexus</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bethany Davis</last_name>
      <phone>+001(404)255-6005</phone>
      <email>Bethany.Davis@GlobalAES.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uptown Research Institute</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Sonnenberg</last_name>
      <phone>+001(773)989-8313-x118</phone>
      <email>jsonnenberg@uptownresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lake Charles Clinical Trials LLC</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Cherry Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Achtyes</last_name>
      <phone>+001(616)965-8200</phone>
      <email>ericachtyes@cherryhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Behavioral Medicine</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leigh Anne Nelson</last_name>
      <phone>+001(816)512-7487</phone>
      <email>nelsonla@umkc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Synexus</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>North Carolina Psychiatric Research Center</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Jarskog</last_name>
      <phone>+001(919)445-0271</phone>
      <email>jarskog@med.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Midwest Clinical Research</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>FutureSearch Trials of Dallas, LP</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Pillar Clinical Research, LLC</name>
      <address>
        <city>Richardson</city>
        <state>Texas</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Office of Dr. Aqeel Hashmi, MD, PA</name>
      <address>
        <city>Richmond</city>
        <state>Texas</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Research Center</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arifulla Khan</last_name>
      <phone>+001(425)453-0404</phone>
      <email>akhan@nwcrc.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lyell McEwin Hospital</name>
      <address>
        <city>Elizabeth Vale</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dennis Liu</last_name>
      <phone>61874854300</phone>
      <email>Dennis.Liu@sa.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suresh Sundram</last_name>
      <phone>61395947796</phone>
      <email>Suresh.Sundram@monashhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital Melbourne</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Monash Alfred Psychiatry Research Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonard Chen</last_name>
      <phone>0390766554</phone>
      <email>leonard.chen@monash.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Raedler</last_name>
      <phone>403210-6899</phone>
      <email>Thomas.Raedler@albertahealthservices.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>BC Mental Health and Addictions Research Institute (University of British Columbia)</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Fredrikson</last_name>
      <phone>604-675-3875</phone>
      <email>diane.fredrikson@vch.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre for Addiction and Mental Health (CAMH)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ofer Agid</last_name>
      <phone>416-535-8501x34862</phone>
      <email>ofer.agid@camh.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IUSMM Institut Universitaire en Sante Mentale de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre Melun</last_name>
      <phone>514-251-4000</phone>
      <email>jpmelun.iusmm@ssss.gouv.qc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CTR Esquirol</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Perrine Brazo</last_name>
      <phone>+33(0)231065018</phone>
      <email>brazo-p@chu-caen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP Dijon-Bourgogne</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoît Trojak</last_name>
      <phone>+33(0)380293769</phone>
      <email>benoit.trojak@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CAB Médical Psyché</name>
      <address>
        <city>Douai</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Desbonnet</last_name>
      <phone>+33(0)327881819</phone>
      <email>philippe.desbonnet654@orange.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP la Colombière</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme Attal</last_name>
      <phone>+33(0)467339702</phone>
      <email>j-attal@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP Saint-Jacques</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marion Chirio-Espitalier</last_name>
      <phone>+33(0)240846396</phone>
      <email>marion.chirioespitalier@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP Pasteur</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Giordana</last_name>
      <phone>+33(0)492037777</phone>
      <email>giordana.b@chu-nice.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GHU Paris Psychiatrie et Neurosciences</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raphaël Gaillard</last_name>
      <phone>+33(0)145658652</phone>
      <email>r.gaillard@ghu-paris.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP Nord</name>
      <address>
        <city>Saint Priest en Jarez</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Fakra</last_name>
      <phone>+33(0)477828852</phone>
      <email>eric.fakra@chu-st-etienne.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Shore Hospital, Takapuna</name>
      <address>
        <city>Takpuna Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wayne Miles</last_name>
      <phone>6494868900</phone>
      <email>wayne.miles@waitematadhb.govt.nz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Holywell Hospital</name>
      <address>
        <city>Antrim</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ciaran Mulholland</last_name>
      <phone>+442890972167</phone>
      <email>Ciaran.Mulholland@northerntrust.hscni.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Fritchie Centre</name>
      <address>
        <city>Cheltenham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robertson Macpherson</last_name>
      <phone>01242634490</phone>
      <email>rob.macpherson@ghc.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Edinburgh Hospital</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald MacIntyre</last_name>
      <phone>01315376000</phone>
      <email>d.macintyre@ed.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth University Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Maudsley Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Panayiota Michalopoulou</last_name>
      <phone>+442032286000</phone>
      <email>panayiota.michalopoulou@kcl.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Warneford Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Belinda Lennox</last_name>
      <phone>+441865613145</phone>
      <email>belinda.lennox@psych.ox.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>New Zealand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 25, 2019</study_first_submitted>
  <study_first_submitted_qc>February 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2019</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>BI 425809</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;.&#xD;
Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.&#xD;
The data shared are the raw clinical study data sets.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>https://www.mystudywindow.com/msw/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

